Prevention of the acetylsalicylic acid-induced changes of the gastric potential difference by the new synthetic prostaglandin E1 analogue rioprostil. 1986

P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann

The protective effect of 50 and 100 micrograms of the synthetic prostaglandin E1 analogue rioprostil (2-decarboxy-2-hydroxymethyl-15-deoxy-16RS-hydroxy-16-methyl PGE1) against the 0.5 and 1 g acetylsalicylic acid (ASA)-induced changes of gastric potential difference (PD) was compared to that of placebo in a double-blind cross-over study in 8 volunteers. Rioprostil 50 and 100 micrograms reduced significantly (p = 0.45) the intensity (area under baseline) of the 0.5 g ASA-induced PD changes. Both doses reduced highly significantly (p = 0.003) the time taken for PD to return to baseline value (15.1 min with 50 micrograms and 17.2 min with 100 micrograms rioprostil vs 43.5 min with placebo). Both doses of rioprostil also reduced significantly (p = 0.04) the PD maximal drop induced by 1 g ASA and reduced highly significantly (p = 0.006) the time taken for PD to return to baseline value (18.9 min with 50 micrograms and 16.8 min with 100 micrograms rioprostil vs 64.6 min with placebo). This study shows that rioprostil protects the stomach against the ASA-induced alterations of the gastric mucosa even when it is given at the same time as ASA and in doses which have only a small antisecretory effect.

UI MeSH Term Description Entries
D008297 Male Males
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D013270 Stomach An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the ESOPHAGUS and the beginning of the DUODENUM. Stomachs

Related Publications

P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann
August 1990, Transplantation proceedings,
P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann
January 1985, Arzneimittel-Forschung,
P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann
January 1987, Digestion,
P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann
December 1991, Transplantation proceedings,
P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann
January 1989, Archives internationales de pharmacodynamie et de therapie,
P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann
January 1986, Clinical therapeutics,
P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann
February 1990, The Australian and New Zealand journal of surgery,
P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann
January 1989, Scandinavian journal of gastroenterology. Supplement,
P Demol, and H D Schmitz, and T R Weihrauch, and J Kuhlmann
January 1989, Scandinavian journal of gastroenterology. Supplement,
Copied contents to your clipboard!